设为首页 加入收藏

TOP

LORBRENA(lorlatinib)tablets(八)
2018-11-23 15:46:55 来源: 作者: 【 】 浏览:10697次 评论:0
ions (7%).
Table 3 Worsening Laboratory Values Occurring in ≥20% of Patients in Study B7461001*
Laboratory Abnormality LORBRENA
All Grades
(%) Grade 3 or 4
(%)
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.
N=number of patients who had at least one on-study assessment for the parameter of interest.
*
Grades using NCI CTCAE version 4.0.

N=292.

N=293.
§
N=291.

N=290.
#
N=284.
Chemistry  
  Hypercholesterolemia† 96 18
  Hypertriglyceridemia† 90 18
  Hyperglycemia‡ 52 5
  Increased AST† 37 2.1
  Hypoalbuminemia§ 33 1.0
  Increased ALT† 28 2.1
  Increased lipase¶ 24 10
  Increased alkaline phosphatase† 24 1.0
  Increased amylase# 22 3.9
  Hypophosphatemia† 21 4.8
  Hyperkalemia‡ 21 1.0
  Hypomagnesemia† 21 0
Hematology  
  Anemia‡ 52 4.8
  Thrombocytopenia‡ 23 0.3
  Lymphopenia† 22 3.4
7 DRUG INTERACTIONS
7.1 Effect of Other Drugs on LORBRENA
Effect of CYP3A Inducers
Concomitant use of LORBRENA with a strong CYP3A inducer decreased lorlatinib plasma concentrations, which may decrease the efficacy of LORBRENA. The effect of concomitant use of LORBRENA with a moderate CYP3A inducer on lorlatinib plasma concentrations has not been studied.
Severe hepatotoxicity occurred in healthy subjects receiving LORBRENA with rifampin, a strong CYP3A inducer. In 12 healthy subjects receiving a single 100 mg dose of LORBRENA with multiple daily doses of rifampin, Grade 3 or 4 increases in ALT or AST occurred in 83% of subjects and Grade 2 increases in ALT or AST occurred in 8%. A possible mechanism for hepatotoxicity is through activation of the pregnane X receptor (PXR) by LORBRENA and rifampin, which are both PXR agonists. The risk of hepatotoxicity with concomitant use of LORBRENA and moderate CYP3A inducers that are also PXR agonists is unknown.
LORBRENA is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA.
Avoid concomitant use of LORBRENA with moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers cannot be avoided, monitor ALT, AST, and bilirubin as recommended [see Dosage and Administration (2.3), Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].
Effect of Strong CYP3A Inhibitors
Concomitant use with a strong CYP3A inhibitor increased lorlatinib plasma concentrations, which may increase the incidence and severity of adverse reactions of LORBRENA. Avoid the concomitant use of LORBRENA with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce LORBRENA dose as recommended [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].
7.2Effect of LORBRENA on Other Drugs
CYP3A Substrates
Concomitant use of LORBRENA decreases the concentration of CYP3A substrates [see Clinical Pharmacology (1
以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 5 6 7 8 9 10 11 下一页 尾页 8/18/18
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇LUXTURNA(voretigene neparvovec-.. 下一篇AEMCOLO(rifamycin)delayed-relea..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位